Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jun;27(2):95-103.
doi: 10.1007/s00399-016-0437-3. Epub 2016 Jun 1.

Implantable cardioverter-defibrillators in congenital heart disease

Affiliations
Review

Implantable cardioverter-defibrillators in congenital heart disease

H Chubb et al. Herzschrittmacherther Elektrophysiol. 2016 Jun.

Abstract

Implantable cardioverter-defibrillators (ICD) have an important role in reducing sudden cardiac death in patients with congenital heart disease (CHD); however, the benefit of ICDs needs to be weighed up against both short-term and long-term adverse effects, which are difficult to evaluate in the heterogeneous CHD population. A tailored approach, taking into account risk stratification and patient-specific factors, is needed to select the most appropriate strategy. This review discusses primary and secondary ICD indications, implantation approaches and long-term follow-up. Recent publications have shed light on the concerns of system longevity, lead extractions, inappropriate shocks and impact on the quality of life. All of these factors require consideration prior to commitment to this long-term treatment strategy.

Implantierbare Kardioverter-Defibrillatoren (ICD) spielen bei Patienten mit angeborenen Herzfehlern (AHF) eine entscheidende Rolle bezüglich der Reduktion des plötzlichen Herztods. Die Vorteile einer ICD-Implantation müssen jedoch den potenziellen akuten, aber auch langfristigen Komplikationen gegenübergestellt werden, was insbesondere bei der Gruppe der AHF-Patienten schwierig ist. Individuelle Strategien, die den patienten-spezifischen Faktoren einerseits und der notwendigen Risikostratifizierung andererseits Rechnung tragen, müssen sorgfältig erarbeitet werden. In diesem Übersichtsartikel werden die ICD-Indikationen zur Primär- und Sekundärprophylaxe, die Implantationstechniken und die Ergebnisse aus der langfristigen Nachbeobachtung diskutiert. Daten aus aktuellen Studien belegen spezifische Limitationen bezüglich Haltbarkeit der Systeme, Umsetzbarkeit von Sondenextraktionen, inadäquaten Schockabgaben und Reduktion der Lebensqualität. Alle diese Faktoren müssen sorgsam abgewogen werden, bevor bei Patienten mit angeborenen Herzfehlern über eine ICD-Implantation als langfristige Behandlungsstrategie entschieden wird.

Keywords: Congenital heart disease; Implantable cardioverter-defibrillator; Sudden cardiac death; Ventricular tachycardia.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Distribution of congenital heart disease (CHD) implantable cardioverter-defibrillator population by CHD lesion. Figures are adapted from the two largest population studies. The 1304 patients reported by Jordan et al with atrial septal defect (ASD) alone are excluded. No patients with VSD alone were reported by Berul et al [3, 13]
Fig. 2
Fig. 2
a Posteroanterior and b lateral radiographs demonstrating transvenous pacing system in an 18 kg child with long QT (LQT) syndrome. Generator has been placed abdominally with lead tunnelled to left subclavian vein (cross). Note redundant loop to accommodate growth (star). c Posteroanterior and d lateral radiographs demonstrating a more complex hybrid system in a 15 kg child with LQT type 3. The first ICD implanted was non-transvenous, with intrapericardial coil (asterisk) and epicardial sense and pacing leads (white arrows). Subsequent failure of the epicardial pacing leads with R‑wave undersensing and rising defibrillation threshold necessitated upgrade of the system with subcutanous coil (scc) and transvenous atrial (a) and ventricular (v) pace and sense leads (c and d courtesy of Jasveer Mangat, Great Ormond Street Hospital, London)
Fig. 3
Fig. 3
Diagram of transvenous implantable cardioverter-defibrillator implanted following Senning repair (patient aged 18 years) for transposition of the great arteries (a). Posteroanterior (b) and lateral (c) radiograph projections. Note ventricular coil (V Coil) placed in the posterior LV via the venous baffle. A atrial sense/pace lead, SVC superior vena cava, RA right atrium. Ao Aorta, PA pulmonary artery, LA left atrium, RV right ventricle and LV left ventricle
Fig. 4
Fig. 4
Patient with severe scoliosis, pulmonary atresia, ventricular septal defect and major aortopulmonary collateral arteries. a Computed tomography and b Balanced steady state free precession (b‑SSFP) magnetic resonance image. c  Anteroposterior and d  lateral radiographs demonstrating subcutaneous implantable cardioverter-defibrillator with excellent shock vector (subcutaneous coil has been placed to the right of the sternum, RV right ventricle, LV left ventricle, SP spine, ST sternum)
Fig. 5
Fig. 5
Diagram of subcutaneous implantable cardioverter-defibrillator and transvenous atrial pacemaker in patient with lateral tunnel Fontan (a). Posteroanterior (b) and lateral (c) radiographs demonstrating single chamber pacemaker (white cross) with lead to systemic venous portion of the right atrium and subcutaneous implantable cardioverter-defibrillator (white star). Figure adapted with permission from Chubb et al [7]
Fig. 6
Fig. 6
Cardiac magnetic resonance imaging in a patient with congenital aortic stenosis (status post-Ross procedure) and magnetic resonance-conditional implantable cardioverter-defibrillator, demonstrating typical results for balance steady state free precession (b‑SSFP) cine imaging. Lead position is indicated by white arrows and the ring artefact related to the generator is seen at the top left of panels (c) and (d). a four chamber view, b short axis, c three chamber view, d right ventricular outflow tract view. RV right ventricle, LV left ventricle, Ao aorta, LA left atrium, PA pulmonary artery

Similar articles

Cited by

References

    1. Atallah J, Erickson CC, Cecchin F, et al. Multi-institutional study of implantable defibrillator lead performance in children and young adults: results of the Pediatric Lead Extractability and Survival Evaluation (PLEASE) study. Circulation. 2013;127:2393–2402. doi: 10.1161/CIRCULATIONAHA.112.001120. - DOI - PubMed
    1. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter – defibrillator for congestive heart failure. N Engl J Med. 2005;352:225–237. doi: 10.1056/NEJMoa043399. - DOI - PubMed
    1. Berul CI, Van Hare GF, Kertesz NJ, et al. Results of a multicenter retrospective implantable cardioverter-defibrillator registry of pediatric and congenital heart disease patients. J Am Coll Cardiol. 2008;51:1685–1691. doi: 10.1016/j.jacc.2008.01.033. - DOI - PubMed
    1. Brugada J, Blom N, Sarquella-Brugada G, et al. Pharmacological and non-pharmacological therapy for arrhythmias in the pediatric population: EHRA and AEPC-Arrhythmia Working Group joint consensus statement. Europace. 2013;15:1337–1382. doi: 10.1093/europace/eut082. - DOI - PubMed
    1. Cannon BC, Friedman RA, Fenrich AL, et al. Innovative techniques for placement of implantable cardioverter - defibrillator leads in patients with limited venous access to the heart. Pace Pacing Clin Electrophysiol. 2006;29:181–187. doi: 10.1111/j.1540-8159.2006.00314.x. - DOI - PubMed

LinkOut - more resources